| ¿µ¹® | Rorschach Test | ÇÑ±Û | ·Î¸£»þÇÏ °Ë»ç |
|---|---|---|---|
| ¼³¸í | »ç°íÀå¾Ö¿Í Á¤¼Àå¾Ö¿¡ ¹Î°¨ÇÑ Åõ»ç°Ë»ç(projective test). °ËÀº»ö°ú ¸î°¡Áö »öÀ¸·Î ÀÌ·ç¾îÁø À×Å©¾ó·è°°Àº µµÇüÀÌ ±×·ÁÁø 10°³ÀÇ Ä«µå¸¦ ÀÌ¿ëÇÑ´Ù. ÇǰËÀÚ¿¡°Ô Ä«µå¸¦ º¸ÀÌ°í º» °Í¿¡ ´ëÇØ ¸»Çϵµ·Ï ÇÑ´Ù. ´ÙÀ½¿¡´Â ¾ó·èÀÇ ¾î´À À§Ä¡°¡ ÇǰËÀÚ°¡ ¸»ÇÑ Áö°¢´ë»óÀ» ¾Ï½ÃÇÏ´ÂÁö ãµµ·Ï ÇÑ´Ù. ÇǰËÀÚÀÇ ´äº¯À» ºÐ¼®ÇÏ¸é ±×ÀÇ »ç°í¿Í Á¤¼»óÅ¿¡ ´ëÇÑ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | Mantoux test | ÇÑ±Û | ¸ÁÅä¿ì°Ë»ç |
|---|---|---|---|
| ¼³¸í | ¼Ò¾Æ¿¡ ÁÖ·Î ½Ç½ÃÇÏ´Â °Ë»ç ¹æ¹ýÀ¸·Î, BCGÁ¢Á¾ÈÄ¿¡³ª ȤÀº °áÇÙ±Õ¿¡ ÇѹøÀÌ¶óµµ ³ëÃâµÈ °æ¿ì¿¡ ¾ç¼º¹ÝÀÀÀ¸·Î ³ª¿Â´Ù. ¿ì¸®³ª¶ó¿¡¼´Â »ýÈÄ 1°³¿ù¿¡ BCG¿¹¹æÁ¢Á¾À» ½ÃÇàÇϹǷΠ´ëºÎºÐ ¾ç¼ºÀ¸·Î ³ª¿À°Ô µÇ³ª, ÀÌ ¿¹¹æÁ¢Á¾À» ¹ÞÁö ¾ÊÀº »óÅ¿¡¼ ¾ç¼ºÀ¸·Î ³ª¿À¸é, °áÇÙ±ÕÀÇ Ä§Åõ¸¦ ÀǽÉÇÒ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | stress test | ÇÑ±Û | ½ºÆ®·¹½º °Ë»ç |
|---|---|---|---|
| ¼³¸í | Çù½ÉÁõÀÌ ÀϾ±â ½¬¿î ȯÀÚ¿¡°Ô¼ ±× Á¤µµ¸¦ ÆÇ´ÜÇϱâÀ§ÇØ ½ÃÇàÇÑ´Ù. ¹æ¹ýÀº °°Àº °÷¿¡¼ ȯÀÚ¸¦ ´Þ¸®µµ·Ï ÇÑ ´ÙÀ½, ¾ó¸¶ÀÇ ¼Óµµ¿¡¼ Ç÷¾ÐÀÌ ¶³¾îÁö°í Çù½ÉÁõ Áõ»óÀÌ ³ªÅ¸³ª´Â°¡¸¦ °Ë»çÇÑ´Ù. ´ë°³ ½ÉÇÒ¼ö·Ï ³·Àº ¼Óµµ¿¡¼µµ Áõ»óÀÌ »¡¸® ³ªÅ¸³´Ù. |
||
| ¿µ¹® | visual field test | ÇÑ±Û | ½Ã¾ß°Ë»ç |
|---|---|---|---|
| ¼³¸í | ´«À» ÇѰ÷¿¡ °íÁ¤½ÃŲ ä, °üÂûÇÒ ¼ö ÀÖ´Â ÁÖº¯°ø°£À» ½Ã¾ß¶ó ÇÑ´Ù. ½Ã¾ß¸¦ °Ë»çÇÏ´Â °¡Àå °£´ÜÇÑ ¹æ¹ýÀº ´ë¸é°Ë»ç(confronting test)ÀÌ´Ù. À̰ÍÀº Çǰ˻çÀÚÀÇ ´«À» °Ë»çÀÚÀÇ ´«¿¡ ¸ÂÃß¾î º¸µµ·Ï ÇÏ¿© ´«À» °íÁ¤½ÃŲä, °Ë»çÀÚ°¡ ¼Õ°¡¶ô³¡À» À§ÂÊ, ¾Æ·¡ÂÊ, ¿ÞÂÊ, ¿À¸¥ÂÊ, ±×¸®°í ºñ½ºµëÈ÷ °æ»çÁø °÷ µîÀ¸·Î ¿Å°Üº¸¾Æ Çǰ˻çÀÚ°¡ °üÂûÇÒ ¼ö ÀÖ´ÂÁö ¿©ºÎ¸¦ Á¤ÇÏ´Â °Ë»ç¹ýÀÌ´Ù. À̺¸´Ù Á¤È®ÇÑ °Ë»ç¹ýÀº ÀÚµ¿½Ä ÄÄÇ»Åͽþ߰˻ç¹ýÀÌ ÀÖ´Ù. ´ë°³, ´«ÀÚüÀÇ ÀÌ»óÀÌ À־ ½Ã¾ß°Ë»ç¿¡¼ ÀÌ»óÀÌ ³ª¿ÀÁö¸¸, ÀÌ¿Ü ³úÀÇ ÀÌ»óÀ¸·Î ½Ã°¢ÀÇ Çü¼º°æ·Î¿¡ ÀÌ»óÀÌ À־ ¿ª½Ã ÀÌ»ó¼Ò°ßÀ» º¸ÀδÙ. |
||
| ¿µ¹® | Draw a person test | ÇÑ±Û | Àι°È ¼º°Ý°Ë»ç |
|---|---|---|---|
| ¼³¸í | Àι°È ¼º°Ý°Ë»ç´Â óÀ½¿¡´Â Áö´É°Ë»ç·Î °³¹ßµÇ¾ú°í, ±× ÈÄ¿¡´Â »ç¶÷ÀÇ ¹«ÀǽÄÀÇ ¿ä¼Ò¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î ¹ßÀüÇÏ¿´´Ù. °Ë»çÀç·á´Â Áö¿ì°³°¡ ÀÖ´Â ¿¬Çʰú ¹éÁö¸¦ ÇǰËÀÚ¿¡°Ô ÁÖ°í, »ç¶÷À» ±×·Áº¸¶ó´Â Áö½Ã¸¦ Çϸç, °Ë»çÀÚ´Â ±×¸®´Â ¼ø¼¿Í Æò°¡¸¦ ±â·ÏÇϰí, ´Ù ±×¸° ÈÄ¿¡´Â ¸ÕÀú¿Í ´Ù¸¥ À̼ºÀ» ±×¸®µµ·Ï ÇÑ´Ù. ÀÌ °Ë»ç¿¡¼ÀÇ ½ÅüÀÇ ¸ð¾çÀº °ð ÀھƻóÀ» ¹Ý¿µÇÑ´Ù´Â ÀÔÀå, ±×¸²¿¡¼ °Á¶µÈ ±â°üÀº ÀÇ»ç¼ÒÅë¼ö´Ü, °ü³äÈ, ¿å±¸Ã¼°è, ¼ºÀû ´É·Â, °¥µî, ÁÂÀý°æÇè, ¼ºÀå·Â µîÀ» ¹Ý¿µÇÑ´Ù°í ÇÑ´Ù. À̰ÍÀº ¾Æµ¿°ú ¼ºÀο¡°Ô °³º°Àû ¶Ç´Â Áý´ÜÀûÀ¸·Î ½Ç½ÃÇÒ ¼ö ÀÖ°í, °£ÆíÇϸ鼵µ À¯ÀÍÇÑ °ÍÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ³úÀÇ ±âÁúÀû º¯È¸¦ ¾Ë¾Æ³»±â À§ÇÑ ¸ñÀûÀ¸·Îµµ ¸¹ÀÌ ÀÌ¿ëµÈ´Ù. |
||
| PAT | Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili... |
|---|---|
| HIT | hemagglutination inhibition test; heparin-induced thrombocytopenia; histamine inhalation test; hyper... |
| IHT | insulin hypoglycemia test; intravenous histamine test; ipsilateral head turning |
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
| TAT | tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex... |
| prolactin release-inhibiting hormone | <chemical> A polypeptide hormone produced in the hypothalamus that inhibits the release of prolactin. Chemical name: Prolactin release-inhibiting factor (12 Dec 1998) |
|---|---|
| somatotropin release-inhibiting factor | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| somatotropin release-inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| deliberate release | Generally refers to putting a genetically manipulated organism into field trials. (14 Nov 1997) |
| sustained release tablet | A drug product formulation that provides the required dosage initially and then maintains or repeats it at desired intervals. Synonym: prolonged action tablet, repeat action tablet. (05 Mar 2000) |
| receptors, histamine | Cell-surface proteins that bind histamine and trigger intracellular changes influencing the behaviour of cells. Histamine receptors are widespread in the central nervous system and in peripheral tissues. Three types have been recognised and designated h1, h2, and h3. They differ in pharmacology, distribution, and mode of action. (12 Dec 1998) |
| receptors, histamine h1 | A class of histamine receptors discriminated by their pharmacology and mode of action. most histamine h1 receptors operate through the inositol phosphate/diacylglycerol second messenger system. Among the many responses mediated by these receptors are smooth muscle contraction, increased vascular permeability, hormone release, and cerebral glyconeogenesis. (12 Dec 1998) |
| receptors, histamine h2 | A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine h2 receptors act via g-proteins to stimulate adenylate cylase. Among the many responses mediated by these receptors are gastric acid secretion, smooth muscle relaxation, inotropic and chronotropic effects on heart muscle, and inhibition of lymphocyte function. (12 Dec 1998) |
| receptors, histamine h3 | A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine h3 receptors were first recognised as inhibitory autoreceptors on histamine-containing nerve terminals and have since been shown to regulate the release of several neurotransmitters in the central and peripheral nervous systems. (12 Dec 1998) |
| histamine | <biochemistry> Formed by decarboxylation of histidine. Potent pharmacological agent acting through receptors in smooth muscle and in secretory systems. Stored in mast cells and released by antigen. (See hypersensitivity). Responsible for the early symptoms of anaphylaxis. Also present in some venoms. (18 Nov 1997) |
| histamine agents | Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells. (12 Dec 1998) |
| histamine agonist | Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (12 Dec 1998) |
| histamine antagonists | Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonist. Classical antihistaminics block the histamine h1 receptors only. (12 Dec 1998) |
| histamine-fast | Indicating the absence of the normal response to histamine, especially in speaking of true gastric anacidity. (05 Mar 2000) |
| histamine flush | Vasodilatation and erythema occurring as a result of release of histamine; thought to be a factor in genesis of flush of carcinoid syndrome. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|